Methylisoindigotin

CAS No. 97207-47-1

Methylisoindigotin( Methylisoindigotin )

Catalog No. M16877 CAS No. 97207-47-1

Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 67 In Stock
5MG 61 In Stock
10MG 85 In Stock
25MG 169 In Stock
50MG 253 In Stock
100MG 398 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Methylisoindigotin
  • Note
    Research use only, not for human use.
  • Brief Description
    Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML).
  • Description
    Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML).(In Vitro):Meisoindigo (Dian III; 5-20 μM; for 24 hours) inhibits growth of the AML cell lines.Meisoindigo (10 μM; for 24 hours) induces apoptosis of acute myeloid leukemia.Meisoindigo (5-10 μM; for 24 hours) causes cell-cycle arrest.Meisoindigo (5-10 μM; for 24 hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells.Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells.(In Vivo):Meisoindigo (Dian III; 50-150 mg/kg; IP; daily; for 14 days) has anti-leukemic activity in vivo.Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain.
  • In Vitro
    Meisoindigo (Dian III; 5-20 μM; for 24?hours) inhibits growth of the AML cell lines. Meisoindigo (10?μM; for 24?hours) induces apoptosis of acute myeloid leukemia. Meisoindigo (5-10?μM; for 24?hours) causes cell-cycle arrest. Meisoindigo (5-10?μM; for 24?hours) increases the cleaved caspase-3 and pro-apoptotic Bak, and decreases Bcl-2 and Bcl-xL levels in HL-60 cells. Meisoindigo (10, 30, 50, 100, 150 μM; 24 hours) interdicts LPS-induced (1 μg/mL) NLRP3 inflammasome activation and M1/M2 polarization through down-regulation of TLR4 pathways after OGD/R in HT-22 and BV2 cells. Cell Viability Assay Cell Line:HL-60, NB4, U937 leukemic cell lines Concentration:5, 10, 15, 20 μM Incubation Time:For 24?hours Result:Inhibited growth of the AML cell lines in a dose- and time-dependent manner.Apoptosis Analysis Cell Line:HL-60 cells Concentration:10?μM Incubation Time:For 24?hours Result:Induced apoptosis of acute myeloid leukemia.Cell Cycle Analysis Cell Line:HL-60 cells Concentration:5, 10?μM Incubation Time:For 24?hours Result:Caused cell-cycle arrest, with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase, in a dose-dependent manner.Western Blot Analysis Cell Line:HL-60 cells Concentration:5, 10?μM Incubation Time:For 24?hours Result:Increased the cleaved caspase-3 and pro-apoptotic Bak, and decreased Bcl-2 and Bcl-xL levels in HL-60 cells.
  • In Vivo
    Meisoindigo (Dian III; 50-150?mg/kg; IP; daily; for 14 days) has anti-leukemic activity in?vivo. Meisoindigo (2, 4, 8, 12 mg/kg; IP; before MCAO and 2 h after reperfusion) significantly reduces infarct volume, ameliorates neurological deficits 3 days after middle cerebral artery occlusion (MCAO) in Wild-type C57BL/6J mice (25-30 g). Meisoindigo reduces edema and lowers AQP4 expression in the brain. Animal Model:NOD/SCID mice, 6-8 weeks old, with HL-60 leukemic cellsDosage:50, 100, 150?mg/kg Administration:IP; daily; for 14 days Result:Had anti-leukemic activity in?vivo.
  • Synonyms
    Methylisoindigotin
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis inducer
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    97207-47-1
  • Formula Weight
    276.29
  • Molecular Formula
    C17H12N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    CN(C1=CC=CC=C1/C2=C3C(NC4=C\3C=CC=C4)=O)C2=O
  • Chemical Name
    (E)-1,1'-dimethyl-[3,3'-biindolinylidene]-2,2'-dione

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee CC, et al. Leuk Lymphoma. 2010 May;51(5):897-905.
molnova catalog
related products
  • Juglanin

    Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.

  • AZD-4877

    AZD-4877 is a potent spindle kinesin (Eg5) inhibitor with an IC50 value of 2 nM. AZD-4877 is an alternative configuration of Ispinesib that inhibits mitosis, induces the formation of a unipolar spindle phenotype, and mediates apoptosis.

  • SCFSkp2-IN-2

    SCFSkp2-IN-2, a Skp2 inhibitor, exhibits a dissociation constant (K_D) of 28.77 μM. It demonstrates antitumor activities by inducing apoptosis in non-small cell lung cancer (NSCLC) cells.